{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:27:20Z","timestamp":1777584440876,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Women with inherited thrombophilia represent more than 15% of the pregnant population. 20\u201350% of pregnancy-related venous thromboembolism (VTE) is associated with at least one inherited thrombophilia, which increases the risk of VTE up to 40-fold depending on the type of thrombophilia and the family history of VTE. Most societies consider homozygosity of factor V Leiden and the prothrombin gene mutation, compound heterozygosity of both, and severe deficiency of factor V Leiden and prothrombin gene mutation as \u201chigh risk\u201d thrombophilia and heterozygous for factor V Leiden or the prothrombin gene mutation as \u201clow risk\u201d thrombophilia. Recommendations on pharmacological prophylaxis vary across international guidelines. According to expert consensus, pharmacological prophylaxis may be indicated if the risk threshold for VTE is\u2009&gt;\u20093% balancing benefit against harm of heparin prophylaxis. In women with low-risk thrombophilia, guidelines recommend pharmacological prophylaxis ante- and postpartum only in cases with a positive family history of VTE or additional VTE risk factors. Most guidelines suggest heparin prophylaxis in women with homozygosity for factor V Leiden mutation or compound thrombophilia regardless of family history of VTE in the antenatal period and for 6\u00a0weeks after delivery. In women with protein S and protein C deficiencies, some guidelines advocate clinical surveillance rather than pharmacological prophylaxis antenatally, while postpartum pharmacological prophylaxis was recommended by all guidelines for women with a positive family history of VTE or with additional risk factors. Pharmacological prophylaxis in women with antithrombin deficiency remains a matter of debate and depends on the subtype and extent of antithrombin deficiency. There is yet no evidence from randomized, controlled trials that pharmacological prophylaxis significantly reduces the risk of VTE in women with inherited thrombophilia. Overestimation of the VTE risk and unnecessary use of heparin is an unsolved problem. Decision-making should also consider the increased risk of bleeding complications and wound hematoma associated with pharmacological thromboprophylaxis. Until there is more evidence for the benefit of pharmacological prophylaxis, the decision for or against prophylaxis remains a case-by-case decision taking into account the patient\u2019s individual risk profile and woman\u2019s preference.<\/jats:p>","DOI":"10.1007\/s00404-026-08389-0","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:36:13Z","timestamp":1775792173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommendations from guidelines for the prevention of venous thromboembolism in pregnant women with inherited thrombophilia"],"prefix":"10.1007","volume":"313","author":[{"given":"Werner","family":"Rath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Tsikouras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0784-1262","authenticated-orcid":false,"given":"Ulrich","family":"Pecks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"8389_CR1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.thromres.2020.07.007","volume":"193","author":"L Andrew","year":"2020","unstructured":"Andrew L, Ainle FN, Blondon M et al (2020) Preventing postpartum venous thromboembolism: a call to active to reduce undue maternal morbidity and mortality. Thromb Res 193:190\u2013197","journal-title":"Thromb Res"},{"key":"8389_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00404-013-2923-8","volume":"289","author":"N Abbasi","year":"2014","unstructured":"Abbasi N, Balayla J, Laporta DP (2014) Trends, risk factors and mortality among women with venous thromboembolism during labour and delivery: a population-based study of 8 million births. Arch Gynecol Obstet 289:275\u2013284","journal-title":"Arch Gynecol Obstet"},{"key":"8389_CR3","first-page":"608","volume":"69","author":"AA Creanga","year":"2017","unstructured":"Creanga AA (2017) Maternal mortality in the developed world: a review of surveillance methods, levels and causes of maternal deaths during 2006\u20132010. Minerva Ginecol 69:608\u2013617","journal-title":"Minerva Ginecol"},{"key":"8389_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","volume":"143","author":"JA Heit","year":"2005","unstructured":"Heit JA, Kobbervig CE, James AW (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143:697\u2013706","journal-title":"Ann Intern Med"},{"key":"8389_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11239-015-1309-0","volume":"41","author":"JM Bates","year":"2016","unstructured":"Bates JM, Middeldorp S, Rodger M, James AM, Greer JA (2016) Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis 41:92\u2013128","journal-title":"J Thromb Thrombolysis"},{"key":"8389_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1055\/a-1717-7663","volume":"42","author":"S Middeldorp","year":"2022","unstructured":"Middeldorp S, Naue C, K\u00f6hler C (2022) Thrombophilia, thrombosis and thromboprophylaxis in pregnancy. For what and in whom? Hamostaseologie 42:54\u201364","journal-title":"Hamostaseologie"},{"key":"8389_CR7","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2016-03-703728","volume":"128","author":"A Gerhardt","year":"2015","unstructured":"Gerhardt A, Scharf RE, Greer JA, Zotz RB (2015) Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium. Blood 128:2343\u20132349","journal-title":"Blood"},{"key":"8389_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2141.2005.05847.x","volume":"132","author":"L Robertson","year":"2005","unstructured":"Robertson L, Wu O, Langhorne P et al (2005) For the Thrombosis Risk and Economic Assessment Thrombophilia Screening (TREATS) Study: thrombophilia in pregnancy: a systematic review. Br J Haematol 132:171\u2013196","journal-title":"Br J Haematol"},{"key":"8389_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/bdrc.21105","volume":"105","author":"LA Parunov","year":"2015","unstructured":"Parunov LA, Soshitova NP, Ovanesov MV et al (2015) Epidemiology of venous thromboembolism (VTE) associated with pregnancy. Birth Defects Res 105:167\u2013184","journal-title":"Birth Defects Res"},{"key":"8389_CR10","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1111\/j.1538-7836.2010.04038.x","volume":"8","author":"AF Jacobson","year":"2010","unstructured":"Jacobson AF, Dahm A, Bergrem A et al (2010) Risk of venous thromboembolism in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J Thromb Haemost 8:2443\u20132449","journal-title":"J Thromb Haemost"},{"key":"8389_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/jth.14549","volume":"17","author":"JM Bistervels","year":"2019","unstructured":"Bistervels JM, Scheres LJJ, Hamulyak EN et al (2019) Sex matters: practice 5P\u2019s when treating young women with venous thromboembolism. J Thromb Haemost 17:1417\u20131429","journal-title":"J Thromb Haemost"},{"key":"8389_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1055\/a-1132-0750","volume":"40","author":"C Hart","year":"2020","unstructured":"Hart C, Bauersachs R, Scholz U et al (2020) Prevention of venous thromboembolism during pregnancy and the puerperium with a special focus on women with hereditary thrombophilia of prior VTE \u2013 position paper of the Working Group in Women\u2019s Health of the Society of Thrombosis and Haemostasis (GTH). Hamostaseologie 40:572\u2013590","journal-title":"Hamostaseologie"},{"key":"8389_CR13","unstructured":"Royal College of Obstetricians and Gynaecologists (2015) Reducing the risk of venous thrombosis during pregnancy and the puerperium. Green-top guideline No. 37a, London, RCOG, available from: https:\/\/www.rcog.org.uk\/media\/qejfhcal\/gtg-37a.pdf"},{"key":"8389_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/AOG.0000000000001579","volume":"128","author":"ME D\u2019Alton","year":"2016","unstructured":"D\u2019Alton ME, Friedman AM, Smiley RM et al (2016) National Partnership for Maternal Safety. Obstet Gynecol 128:688\u2013698","journal-title":"Obstet Gynecol"},{"key":"8389_CR15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000002706","volume":"132","author":"ACOG Practice Bulletin No. 197","year":"2018","unstructured":"ACOG Practice Bulletin No. 197 (2018) Inherited thrombophilia in pregnancy. Obstet Gynecol 132:e1\u2013e17","journal-title":"Obstet Gynecol"},{"issue":"2) Suppl","key":"8389_CR16","doi-asserted-by":"publisher","first-page":"e691S","DOI":"10.1378\/chest.11-2300","volume":"141","author":"SM Bates","year":"2012","unstructured":"Bates SM, Greer IA, Middeldorp S (2012) VTE, Thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 141(2) Suppl):e691S-735S","journal-title":"Chest"},{"key":"8389_CR17","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","volume":"2","author":"JM Bates","year":"2018","unstructured":"Bates JM, Rajasekhar A, Middeldorp S et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2:3317\u20133339","journal-title":"Blood Adv"},{"key":"8389_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S1701-2163(15)30569-7","volume":"36","author":"W-S Chan","year":"2014","unstructured":"Chan W-S, Rey F, Kent NE (2014) SOGC Clinical Practice Guideline No. 308: venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 36:527\u2013553","journal-title":"J Obstet Gynaecol Can"},{"key":"8389_CR19","unstructured":"AWMF S3-Leitlinie: Prophylaxe der ven\u00f6sen Thromboembolien (VTE) Langversion 4.0.2025. https:\/\/register.awmf.org\/assets\/guidelines\/003-001l_S3 prophylaxe-venoese-Thromboembolie-VTE-2016\u201301.pdf"},{"key":"8389_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4452","volume":"359","author":"FN Croles","year":"2017","unstructured":"Croles FN, Nasserinejad K, Duvekot JJ et al (2017) Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ 359:j4452","journal-title":"BMJ"},{"key":"8389_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-018-0180.6","volume":"16","author":"A Kotaska","year":"2018","unstructured":"Kotaska A (2018) Venous thromboembolism prophylaxis may causes more harm than benefit: an evidence-based analysis of Canadian and international guidelines. Thromb J 16:25. https:\/\/doi.org\/10.1186\/s12959-018-0180.6","journal-title":"Thromb J"},{"key":"8389_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/1471-0528.18229","volume":"132","author":"LA Magee","year":"2025","unstructured":"Magee LA, Arya R, Boag C et al (2025) Pregnancy-related venous thromboembolism risk perception and prevention in risk-averse times \u2013 significant change required: a commentary. BJOG 132:1341\u20131345","journal-title":"BJOG"},{"key":"8389_CR23","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/1471-0528.15150","volume":"125","author":"A Kotaska","year":"2018","unstructured":"Kotaska A (2018) Postpartum venous thromboembolism prophylaxis may cause more harm than benefit: a critical analysis of international guidelines through an evidence-based lens. BJOG 125:1109\u20131116","journal-title":"BJOG"},{"key":"8389_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/OGX.0000000000001428","volume":"80","author":"E Boureka","year":"2025","unstructured":"Boureka E, Arvanitaki A, Ralli E-E et al (2025) Prevention of venous thromboembolism in pregnancy and the puerperium: a comparative review of guidelines. Obstet Gynecol Surv 80:589\u2013605","journal-title":"Obstet Gynecol Surv"},{"key":"8389_CR25","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1111\/1471-0528.13706","volume":"123","author":"KL Palmerola","year":"2016","unstructured":"Palmerola KL, D\u2019Alton ME, Brock CO, Friedman AM (2016) A comparison of recommendations for pharmacological thromboembolism prophylaxis after cesarean delivery from three major guidelines. BJOG 123:2157\u20132163","journal-title":"BJOG"},{"key":"8389_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1086\/s12884-025-07246-3","volume":"25","author":"S Ephraums","year":"2025","unstructured":"Ephraums S, Dasgupta A, Korah S et al (2025) A comparison of international clinical practice guideline for postpartum venous thromboembolism prophylaxis. BMC Pregnancy Childbirth 25:150. https:\/\/doi.org\/10.1086\/s12884-025-07246-3","journal-title":"BMC Pregnancy Childbirth"},{"key":"8389_CR27","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/S0140-6736(22)02128-6","volume":"400","author":"JM Bistervels","year":"2022","unstructured":"Bistervels JM, Buchm\u00fcller A, Wiegers HRG et al (2022) Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and postpartum women with a history of venous thromboembolism (Highlow study): an open-label multicentre, randomized, controlled trial. Lancet 400:1777\u20131787","journal-title":"Lancet"},{"key":"8389_CR28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(14)60793-5","volume":"384","author":"MA Rodger","year":"2014","unstructured":"Rodger MA, Hague WM, Kingdom J et al (2014) Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 384:1673\u20131683","journal-title":"Lancet"},{"key":"8389_CR29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1600-0412.2011.01098.x","volume":"90","author":"PG Lindqvist","year":"2011","unstructured":"Lindqvist PG, Bremme K, Hellgren M (2011) Working Group on Hemostatic Disorders, Swedish Society of Obstetrics and Gynecology: efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of venous thromboembolism. Acta Obstet Gynecol Scand 90:648\u2013659","journal-title":"Acta Obstet Gynecol Scand"},{"key":"8389_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000408","volume":"3","author":"S Davis","year":"2024","unstructured":"Davis S, Goodacre S, Horner D et al (2024) Effectiveness and cost effectiveness of pharmacological thromboprophylaxis for medical inpatients: decision analysis modelling study. BMJ Med 3:e000408","journal-title":"BMJ Med"},{"key":"8389_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.amjmed.2004.12.009","volume":"118","author":"JA Johnston","year":"2005","unstructured":"Johnston JA, Brill-Edwards P, Ginsberg JS et al (2005) Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism. Am J Med 118:503\u2013514","journal-title":"Am J Med"},{"key":"8389_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045672","volume":"11","author":"A Pandor","year":"2021","unstructured":"Pandor A, Tonkins M, Goodacre S et al (2021) Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review. BMJ Open 11:e045672","journal-title":"BMJ Open"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08389-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-026-08389-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08389-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:54:51Z","timestamp":1777406091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-026-08389-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8389"],"URL":"https:\/\/doi.org\/10.1007\/s00404-026-08389-0","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The ORCID for author Ulrich Pecks has been added.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"162"}}